|
|
||||||||
From Institut National de la Santé et de la Recherche Médicale U 289, Hôpital de la Salpêtière, Paris, France.
Address correspondence and reprint requests to Dr. Etienne C. Hirsch, INSERM U 289, Hôpital de la Salpêtrière, 47 Boulevard de lHôpital, 75013 Paris, France; e-mail: hirsch{at}ccr.jussieu.fr
Fas-associating protein with a death domain (FADD) is a proximal adaptor protein of the tumor necrosis factor (TNF) receptor family death pathway. This human postmortem study showed a significant decrease in the percentage of FADD-immunoreactive dopaminergic (DA) neurons in the substantia nigra pars compacta of patients with PD compared with controls (-24.8%). This decrease correlated with the known selective vulnerability of nigral DA neurons in PD, suggesting that this pathway contributes to the susceptibility of DA neurons in PD to TNF-mediated apoptosis.
This article has been cited by other articles:
![]() |
F. Simunovic, M. Yi, Y. Wang, L. Macey, L. T. Brown, A. M. Krichevsky, S. L. Andersen, R. M. Stephens, F. M. Benes, and K. C. Sonntag Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology Brain, July 1, 2009; 132(7): 1795 - 1809. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-y. Yu, M. Saarma, and U. Arumae Death Receptors and Caspases But Not Mitochondria Are Activated in the GDNF- or BDNF-Deprived Dopaminergic Neurons J. Neurosci., July 23, 2008; 28(30): 7467 - 7475. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Jenner Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease Neurology, October 12, 2004; 63(7_suppl_2): S13 - S22. [Full Text] |
||||
![]() |
R. Kassis, F. Larrous, J. Estaquier, and H. Bourhy Lyssavirus Matrix Protein Induces Apoptosis by a TRAIL-Dependent Mechanism Involving Caspase-8 Activation J. Virol., June 15, 2004; 78(12): 6543 - 6555. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hayley, S. J. Crocker, P. D. Smith, T. Shree, V. Jackson-Lewis, S. Przedborski, M. Mount, R. Slack, H. Anisman, and D. S. Park Regulation of Dopaminergic Loss by Fas in a 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease J. Neurosci., February 25, 2004; 24(8): 2045 - 2053. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Hrycaj, I. Korczowska, and J. K. Lacki Severe Parkinson's disease in rheumatoid arthritis patient treated with infliximab Rheumatology, May 1, 2003; 42(5): 702 - 703. [Full Text] [PDF] |
||||
![]() |
G. A. de Erausquin, K. Hyrc, D. A. Dorsey, D. Mamah, M. Dokucu, D. H. Masco, T. Walton, K. Dikranian, M. Soriano, J. M. G. Verdugo, et al. Nuclear Translocation of Nuclear Transcription Factor-kappa B by alpha -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors Leads to Transcription of p53 and Cell Death in Dopaminergic Neurons Mol. Pharmacol., April 1, 2003; 63(4): 784 - 790. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |